Nuvation Bio Q2 revenue beats estimates on IBTROZI growth

Nuvation Bio

06/08/2026 12:53

Overview
U.S. oncology drug developer's Q2 revenue rose and beat analyst expectations
Company posted Q2 net loss of $62.8 mln, or $0.18 per share
Q2 revenue growth driven by increased IBTROZI adoption in ROS1+ NSCLC

Outlook
Company did not provide specific financial guidance for the current or future periods

Result Drivers
IBTROZI ADOPTION - Q2 net product revenue rose 25% QoQ, driven by increased IBTROZI use in ROS1+ NSCLC, especially among TKI-naïve patients
COLLABORATION AND LICENSE REVENUE - Higher collaboration and license agreement revenue, mainly from increased product supply and royalties
OPERATING EXPENSES - Higher research, development, and administrative costs due to increased clinical trial activity, headcount, and professional fees

Company press release: ID:nPn3yFsRna

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$31.69 mln
$27.51 mln (9 Analysts)
Q2 Loss Per Share
 
$0.18
 
Q2 Net Loss
 
$62.84 mln
 
Q2 Income from Pperations
 
-$51.04 mln
 
Q2 Pretax Loss
 
$62.84 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Nuvation Bio Inc. is $12.00, about 88.4% above its August 5 closing price of $6.37

Reuters Recommended Reads
Aug 5 - Coherus Oncology Q2 revenue rises 40% on higher LOQTORZI volume, but slightly falls below estimates
Aug 4 - Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Aug 5 - Geron's Q2 revenue rises on RYTELO growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)